Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Charles Romp Biography and Net Worth

EVP of Seagen

Chip leads our U.S. commercial organization and has over 27 years of biotechnology and pharmaceutical experience. Since joining Seagen to build our original ADCETRIS sales team, he has consistently provided decisive leadership and clear direction, and fostered a team culture that is true to our patient-centric values. Chip has continued to deliver strong results with the expansion of our portfolio to three brands: ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), and TUKYSA® (tucatinib).

Previously, Chip was a National Sales Director for oncology and immunology products at Genentech, including Avastin® (bevacizumab) and Rituxan® (rituximab). While at Genentech, he also led deployment of the BioOncology sales forces. Earlier in his career, Chip was a Product Manager at GE Medical Systems and a pharmaceutical sales representative at Sankyo Park Davis and GlaxoSmithKline.

Chip holds an M.B.A. from Saint Leo University (formerly Saint Leo College) and a B.A. from the University of Florida.

What is Charles R. Romp's net worth?: The estimated net worth of Charles R. Romp is at least $15.81 million as of September 21st, 2023. Mr. Romp owns 69,111 shares of Seagen stock worth more than $15,808,450 as of December 22nd. This net worth evaluation does not reflect any other assets that Mr. Romp may own. Additionally, Mr. Romp receives an annual salary of $1,080,000.00 as EVP at Seagen. Learn More about Charles R. Romp's net worth.
How old is Charles R. Romp?: Mr. Romp is currently 55 years old. There are 4 older executives and no younger executives at Seagen. The oldest executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who is 67 years old. Learn More on Charles R. Romp's age.
What is Charles R. Romp's salary?: As the EVP of Seagen Inc., Mr. Romp earns $1,080,000.00 per year. There are 4 executives that earn more than Mr. Romp. The highest earning executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer and President of Research & Development, who commands a salary of $2,480,000.00 per year. Learn More on Charles R. Romp's salary.
How do I contact Charles R. Romp?: The corporate mailing address for Mr. Romp and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on Charles R. Romp's contact information.
Has Charles R. Romp been buying or selling shares of Seagen?: Charles R. Romp has not been actively trading shares of Seagen over the course of the past ninety days. Learn More on Charles R. Romp's trading history.
Who are Seagen's active insiders?: Seagen's insider roster includes Roger Dansey (Insider), David Epstein (CEO), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Charles R. Romp Insider Trading History at Seagen

Charles R. Romp Buying and Selling Activity at Seagen

Seagen Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Today's Range

Now: $228.74

$228.74

50 Day Range

MA: $228.74

$228.74

2 Week Range

Now: $228.74

$123.77

$228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad